Penumbra, Inc. (NYSE:PEN) Given Average Recommendation of "Hold" by Analysts
Analysts have issued a consensus "Hold" rating for Penumbra, Inc. (NYSE:PEN), with 13 out of 17 firms recommending hold, three recommending buy, and one recommending sell. The average 12-month price target is $367.07. Despite quarterly revenue of $390.05 million exceeding estimates, the company missed EPS forecasts, reporting $0.88 against a $1.16 consensus.
Penumbra (NYSE: PEN) grants president 3,060 RSUs with multi-year vesting
Penumbra Inc. (PEN) granted its President, Shruthi Narayan, 3,060 Restricted Stock Units (RSUs) on August 17, 2026, under the company's 2014 Equity Incentive Plan. These RSUs will vest in four equal annual tranches starting August 15, 2027, contingent on continued service, with an alternative vesting schedule if a specific merger agreement dated January 14, 2026, closes. Following this grant, the President beneficially owns 33,880 common shares, including 65 shares purchased through the Employee Stock Purchase Plan.
NINE MASTS CAPITAL Ltd Acquires New Position in Penumbra, Inc. $PEN
NINE MASTS CAPITAL Ltd recently acquired a new position in Penumbra, Inc. (NYSE:PEN), purchasing 23,264 shares valued at approximately $7.35 million in the second quarter. This investment makes Penumbra the 20th largest holding for NINE MASTS CAPITAL Ltd, representing about 0.06% of Penumbra and 0.7% of the fund's total holdings. Despite analysts maintaining a "Hold" rating and the company missing earnings per share estimates, institutional investors collectively own 88.88% of Penumbra.
Citizens Financial Group Inc. RI Invests $9.88 Million in Penumbra, Inc. $PEN
Citizens Financial Group Inc. RI has acquired a new stake of 31,286 shares in Penumbra, Inc. (NYSE:PEN) worth approximately $9.88 million during the second quarter. Other institutional investors also adjusted their holdings in Penumbra, with the company currently having 88.88% institutional ownership. Analysts have a consensus "Hold" rating for Penumbra with an average target price of $367.07, despite the company missing its Q2 earnings per share estimate.
Fidelity Advisor Mid Cap II Fund's Penumbra Inc(PEN) Holding History
This article details Fidelity Advisor Mid Cap II Fund's historical holdings in Penumbra Inc (PEN). As of March 31, 2026, the fund held no shares, having made three purchases and two sales of the stock since 2025Q1. Despite currently holding no shares, the fund realized an estimated gain of $3.04 million, or 25.33%, on its past PEN transactions.
Penumbra, Inc. (PEN) Stock Analysis: Exploring a 10.65% Potential Upside in the Healthcare Sector
Penumbra, Inc. (NYSE: PEN) is a leading medical device company with a $12.88 billion market capitalization, known for its thrombectomy systems and neurovascular products. The company shows strong revenue growth of 14.90% and a 11.37% Return on Equity, positioning it as an attractive investment despite not offering dividends. Analysts project a potential 10.65% upside with a consensus target price of $361.83, driven by its innovation and market expansion strategies.
Alberta Investment Management Corp Invests $10.46 Million in Penumbra, Inc. $PEN
Alberta Investment Management Corp recently acquired a new position in Penumbra, Inc. (NYSE:PEN), purchasing 33,120 shares valued at approximately $10.46 million. This investment comes as institutional investors and hedge funds now collectively own 88.88% of Penumbra, while analysts maintain a "Hold" consensus rating with an average price target of $367.07. Despite a 14.9% year-over-year revenue increase in its latest quarter, Penumbra's earnings per share of $0.88 missed the consensus estimate of $1.16.
Technical Reactions to PEN Trends in Macro Strategies
This article provides a technical analysis of Penumbra Inc. (NYSE: PEN), indicating neutral near and mid-term readings but a positive long-term bias. It highlights a 27.2:1 risk-reward setup targeting a 7.8% gain against 0.3% risk. The analysis includes institutional trading strategies for position trading, momentum breakouts, and risk hedging, along with multi-timeframe signal analysis.
Should Penumbra’s RED 68 Catheter Recall and Margin Strain Require Action From Penumbra (PEN) Investors?
Penumbra, Inc. recently initiated a voluntary Class II recall of its RED 68 Reperfusion Catheter due to manufacturing issues, which follows a quarter where the company reported higher sales but lower net income and reduced earnings per share. This article examines how the recall could impact Penumbra's growth and margin narrative, particularly in light of existing profitability pressures and investor expectations for long-term growth in stroke and vascular interventions. The recall highlights product quality and regulatory scrutiny as key risks to Penumbra's investment profile.
Should Penumbra’s RED 68 Catheter Recall and Margin Strain Require Action From Penumbra (PEN) Investors?
Penumbra, Inc. recently initiated a Class II recall of its RED 68 Reperfusion Catheter due to manufacturing issues, coinciding with a quarter reporting higher sales but lower net income and reduced earnings per share. This recall adds to existing margin pressures and raises concerns about product quality and regulatory scrutiny, potentially impacting the company's previously optimistic growth and profitability forecasts. Investors are advised to consider these developments as they could influence hospital trust and future device adoption, potentially reinforcing cautious analyst views on Penumbra's future performance.
Penumbra, Inc. (PEN) stock price, news, quote and history
This article provides a comprehensive overview of Penumbra, Inc. (PEN), a medical device company, including its current stock price, historical data, financial performance, and analyst insights. It details the company's product offerings in neurosurgical and peripheral thrombectomy devices and outlines key financial metrics and comparisons with other medical device companies. The report also highlights Penumbra's latest quarterly earnings and future growth estimates.
Penumbra, Inc. (PEN) Stock Analysis: Evaluating the 11.45% Potential Upside in Medical Devices
Penumbra, Inc. (NYSE: PEN), a medical devices company with a $12.79 billion market cap, shows a potential upside of 11.45% based on analyst target prices. Despite a premium valuation with a forward P/E of 52.95, the company exhibits strong performance with 14.90% revenue growth and robust free cash flow, reinvesting profits for innovation rather than paying dividends. Technical indicators suggest positive momentum, though the stock might be overbought, making it a compelling option for growth-oriented investors in the healthcare sector.
Should Penumbra’s RED 68 Catheter Recall and Margin Strain Require Action From Penumbra (PEN) Investors?
Penumbra, Inc. recently initiated a voluntary Class II recall of its Penumbra System RED 68 Reperfusion Catheter due to manufacturing issues, shortly after reporting higher quarterly sales but lower net income and reduced earnings per share. This recall adds to existing margin pressures and raises concerns about product quality and regulatory scrutiny, impacting Penumbra's growth narrative. Investors should consider these developments in light of the company's previously optimistic forecasts.
Bank of America Corp DE Sells 46,436 Shares of Penumbra, Inc. $PEN
Bank of America Corp DE reduced its stake in Penumbra, Inc. by 15.2% in the first quarter, selling 46,436 shares and retaining 259,775 shares valued at approximately $85.3 million. Despite Penumbra reporting a 14.9% year-over-year revenue increase to $390.05 million, its earnings per share of $0.88 missed analyst estimates of $1.16. The stock currently holds a consensus "Hold" rating from analysts with an average price target of $367.07.
Royal Bank of Canada Decreases Holdings in Penumbra, Inc. $PEN
Royal Bank of Canada significantly reduced its stake in Penumbra, Inc. by nearly 50% in the first quarter, selling 39,656 shares and retaining 39,794 shares valued at $13.1 million. This comes as Penumbra reported mixed financial results, with revenue slightly above estimates but EPS missing consensus. Analyst sentiment for Penumbra remains cautious, with a consensus "Hold" rating and an average price target of $367.07.
Penumbra Inc (PEN) Stock News Today
This article provides current stock information for Penumbra Inc (PEN), including its latest stock price, market capitalization, and P/E ratio. It notes that this page will feature news, earnings, analyst ratings, and key developments related to PEN stock, with more updates expected soon. The article is primarily a placeholder for future news and analysis on the company.
The Manufacturers Life Insurance Company Sells 65,658 Shares of Penumbra, Inc. $PEN
The Manufacturers Life Insurance Company significantly reduced its stake in Penumbra, Inc. by selling 65,658 shares, now holding 20,047 shares valued at $6.6 million. Despite collective institutional ownership of 88.88%, analyst sentiment for Penumbra is mixed with a "Hold" consensus and a target price of $367.07. Penumbra reported quarterly revenue of $390.05 million, exceeding estimates, but missed earnings per share forecasts with $0.88 against a $1.16 consensus.
Penumbra, Inc. (PEN) Stock Forecasts
This article provides a stock forecast for Penumbra, Inc. (PEN), a US-based company that designs and markets thrombectomy and embolization devices. The report highlights the company's focus on minimally invasive devices for hospitals and physicians. Access to the full report is exclusive to Yahoo Finance Silver subscribers.
THUNDER study demonstrates Penumbra's Thunderbolt CAVT system is safe and effective for stroke care
Penumbra, Inc. announced positive results from its THUNDER study, evaluating the safety and effectiveness of its Thunderbolt computer-assisted vacuum thrombectomy (CAVT) system for stroke patients with emergent large vessel occlusion (ELVO). The study showed high rates of successful reperfusion and complete clot ingestion with low complication rates, suggesting a significant advancement in stroke treatment options. The Thunderbolt system, which introduces modulated aspiration, recently received U.S. FDA clearance and CE Mark.
Trading the Move, Not the Narrative: (PEN) Edition
The article provides a detailed AI-driven analysis for Penumbra Inc. (NYSE: PEN), highlighting near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and specific support and resistance levels. The analysis emphasizes a significant risk-reward setup, targeting a 7.8% gain versus 0.3% risk.
Did Penumbra's (PEN) Voluntary RED 68 Catheter Recall Just Shift Its Investment Narrative?
Penumbra, Inc. recently initiated a voluntary Class II recall of its RED 68 Reperfusion Catheter due to manufacturing issues, raising questions about product quality and future regulatory scrutiny. This recall follows a Q2 2026 report showing higher sales but lower net income, suggesting operational risks could now outweigh growth prospects. Investors are advised to consider these new manufacturing concerns alongside Penumbra's long-term growth narrative in minimally invasive interventions.
Did Penumbra's (PEN) Voluntary RED 68 Catheter Recall Just Shift Its Investment Narrative?
Penumbra, Inc. recently initiated a voluntary Class II recall of its RED 68 Reperfusion Catheter due to manufacturing issues that may cause the device to fracture. This recall follows a quarter where the company reported higher sales but lower net income, raising concerns about product quality control and potential regulatory scrutiny. The article suggests this event could significantly influence Penumbra's investment narrative, challenging analyst forecasts and highlighting operational risks alongside growth opportunities.
Amundi Buys 259,936 Shares of Penumbra, Inc. $PEN
Amundi increased its stake in Penumbra, Inc. by 302.9% in the first quarter, purchasing 259,936 additional shares to hold a total of 345,758 shares valued at $113.5 million. Institutional investors now own 88.88% of the company. Despite Penumbra's recent quarterly revenue slightly exceeding estimates, its earnings per share missed the consensus forecast.
Penumbra Inc 2Q 2026: Revenue $390.05M, EPS $0.88— 10-Q Summary
Penumbra Inc (PEN) reported its second-quarter 2026 results, with revenue reaching $390.05 million, a 14.9% increase year-over-year. Despite revenue growth, net income and diluted EPS decreased to $34.81 million and $0.88, respectively, due to strategic investments. The company also announced a merger agreement to be acquired by Boston Scientific for approximately $14.5 billion.
Penumbra (NYSE: PEN) Q2 revenue reaches $390.0 million amid Boston Scientific deal
Penumbra Inc. reported Q2 2026 revenue of $390.0 million, a 14.9% increase year-over-year, driven by strong growth in thrombectomy and embolization products. The company will not provide full-year 2026 financial guidance or host a conference call due to its pending acquisition by Boston Scientific Corporation, which also led to $6.9 million in acquisition-related expenses during the quarter. Despite a net income of $34.8 million, this was lower than the previous year, with the company’s balance sheet showing increased cash and marketable investments.
Penumbra, Inc. Revenue Breakdown – NYSE:PEN
This article details Penumbra, Inc.'s (NYSE: PEN) revenue breakdown, highlighting that the company generated $1.40 billion USD last year. Its top-performing segment was Thrombectomy, contributing $947.92 million USD, and the United States was its largest regional contributor with $1.09 billion USD.
Press Release: Penumbra, Inc. Reports Second Quarter 2026 Financial Results
Penumbra, Inc. announced its financial results for the second quarter of 2026. The company reported significant revenue growth, driven by strong performance across its neuro and vascular businesses. This press release provides a detailed overview of their financial achievements and key operational highlights during the quarter.
Penumbra Q2 revenue rises 14.9% amid Boston Scientific acquisition plans
Penumbra, Inc. reported a 14.9% increase in Q2 2026 revenue to $390 million, driven by strong sales in its thrombectomy and embolization products, and achieved a net income of $34.8 million despite acquisition-related costs. The company will not issue full-year guidance or host a conference call due to its pending acquisition by Boston Scientific. This performance underscores Penumbra's strong market position as the acquisition proceeds.
Penumbra Inc earnings missed by $0.28, revenue topped estimates
Penumbra Inc (NYSE: PEN) reported its Q2 earnings, missing analyst EPS estimates by $0.28 with an EPS of $0.88 against an expected $1.16. However, the company's revenue for the quarter exceeded expectations, coming in at $390.04 million compared to the consensus estimate of $389.61 million. The stock is down 1.69% in the last three months but up 26.78% over the past year, with its financial health rated as "great performance" by InvestingPro.
Penumbra Q2 revenue rises 14.9 percent to $390.0 million
Penumbra (PEN) reported a 14.9% increase in Q2 2026 revenue to $390.0 million, although net income decreased to $34.8 million from $45.3 million in the prior year. The company will not provide full-year guidance due to its pending acquisition by Boston Scientific Corporation. Insider trading activity shows sales, while institutional investors have mixed positions, with some large firms significantly reducing their stakes.
Earnings Flash (PEN) Penumbra, Inc. Reports Q2 Revenue $390.0M, vs. FactSet Est of $389.6M
Penumbra, Inc. (PEN) reported its second-quarter revenue of $390.0 million, surpassing the FactSet estimate of $389.6 million. The company specializes in thrombectomy devices for conditions like ischemic stroke and venous thromboembolism. Penumbra's products are sold globally through direct sales and distributors, focusing on improving clinical outcomes for patients.
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
Penumbra, Inc. reported its financial results for the second quarter ended June 30, 2026, announcing total revenue of $390.0 million, a 14.9% increase year-over-year. The company's thrombectomy revenue grew by 12.5% to $259.0 million, and embolization and access revenue increased by 20.0% to $131.1 million. Due to a pending acquisition by Boston Scientific Corporation, Penumbra will not provide full-year 2026 financial guidance or host a conference call.
Magnendo Secures $18M Series A Financing to Develop Robotic Stroke Intervention Tech
Magnendo, an MIT spinout, has secured $18 million in Series A financing led by Penumbra, Inc. The funding will advance its magnetic robotic navigation platform designed for neuro-endovascular procedures to improve stroke intervention. This technology aims to make navigating complex vascular anatomy faster and more reliable, preparing the system for its first-in-human clinical studies.
Penumbra Inc (PEN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Penumbra Inc (PEN), noting its current valuation score of 7.08, which ranks 169 out of 199 in the Healthcare Equipment & Supplies industry. The company's current P/E ratio is 73.09, showing significant deviation from its recent high and low. Data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Early Pulmonary Embolism Thrombectomy Device Market : Global Industry Analysis and Opportunity Assessment, 2036
The global Early Pulmonary Embolism Thrombectomy Device Market is projected to grow from USD 1,039.8 million in 2026 to USD 2,952.6 million by 2036, at an 11.0% CAGR. This growth is driven by faster identification and treatment decisions for intermediate-high risk PE patients, with early-stage thrombectomy and aspiration devices being key segments. Competition in the market is concentrated among companies like Stryker/Inari, Penumbra, AngioDynamics, Imperative Care, and Inquis Medical, supported by increasing regulatory clearances and a focus on established clinical protocols for adoption.
PEN|Penumbra Inc|Price:317.552|Chg%:-2.438
This article provides a comprehensive stock analysis of Penumbra Inc (PEN), highlighting its strong fundamentals, high growth potential, and relatively fair valuation. It notes that institutional ownership is high and analysts currently rate the stock as "Hold" with a target price suggesting moderate upside. The company's strengths include consistent revenue and profit growth, while a risk mentioned is institutional selling.
Penumbra Inc (PEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Penumbra Inc (PEN), focusing on its stock price momentum, support and resistance levels, and insights from various technical indicators and moving averages. It highlights that PEN's current price momentum score is 1.46, ranking 198 out of 199 in its industry, with the stock trading between a resistance level of 322.66 and a support level of 316.06. The analysis also details signals from indicators like MACD, RSI, and Stochastics, and provides a breakdown of buy and sell signals from different moving averages, concluding with a "Neutral" overall signal based on these factors.
Penumbra Releases Results of CAVT System Study for Stroke Patients
Penumbra, Inc. announced the results of the Thunder study, evaluating its Thunderbolt computer-assisted vacuum thrombectomy (CAVT) system for stroke patients with emergent large vessel occlusion (ELVO). The study demonstrated high revascularization rates (87.5% achieving mTICI 2b-3), short procedure times (median 20 min), and a low complication rate, suggesting a significant advancement in stroke treatment. Thunderbolt, which recently received FDA clearance and CE Mark, utilizes modulated aspiration technology to effectively remove clots.
Penumbra Inc (PEN) Income Statement
This article provides a detailed income statement for Penumbra Inc (PEN), offering both quarterly and annual financial data spanning several years. It includes key metrics such as total revenue, cost of revenue, operating expenses, research and development expenses, depreciation, operating profit, and net income, allowing for analysis of the company's financial performance and operational efficiency. The statement is accompanied by FAQs explaining how to interpret the data and highlighting important metrics for investors.
Penumbra Inc (PEN) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the major shareholders and institutional holdings of Penumbra Inc (PEN). It lists the top five shareholders by proportion, including Fidelity Management & Research Company LLC and BlackRock Institutional Trust Company, N.A., and breaks down shareholder types. The report also provides a historical overview of institutional shareholding and recent shareholder activity with changes in holdings.
Penumbra Inc (PEN) Cash Flow
This article provides a detailed cash flow statement for Penumbra Inc (PEN), breaking down operating, investing, and financing activities on a quarterly and annual basis. It also offers definitions and explanations of key cash flow metrics, such as operating cash flow, investing cash flow, financing cash flow, and free cash flow, along with Penumbra's performance in these areas. Investors can use this data to assess the company's financial health and stability.
WHITEBOX ADVISORS LLC's Penumbra Inc(PEN) Holding History
As of Q1 2026, WHITEBOX ADVISORS LLC holds 445,001 shares of Penumbra Inc (PEN), valued at $146.12 million, constituting 4.96% of its stock portfolio. The firm's initial purchase was in 2026Q1 at an average price of $338.61 per share. Based on the current price of $319.49, WHITEBOX ADVISORS LLC has an estimated loss of $8.51 million, or -5.65%, on its PEN holdings.
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
A new study called THUNDER showed that Penumbra's THUNDERBOLT computer-assisted vacuum thrombectomy (CAVT) system is safe and effective for treating stroke patients with emergent large vessel occlusion (ELVO). The study, which enrolled 216 patients across 29 U.S. centers, demonstrated high revascularization rates, short procedure times, and low complication rates for the THUNDERBOLT system. These findings suggest that modulated aspiration technology could significantly improve treatment outcomes for stroke patients.
Magnendo Corp. announced that it has received $18 million in funding from Penumbra, Inc. and other investors
Magnendo Corp. has secured $18 million in funding, led by new investor Penumbra, Inc. The funding round, which closed on July 24, 2026, also included participation from other institutional investors. Magnendo Corp. issued convertible preferred stock as part of this transaction.
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
Penumbra, Inc. announced the results of its THUNDER study, which evaluated the safety and effectiveness of its THUNDERBOLT computer assisted vacuum thrombectomy (CAVT) system for stroke patients with emergent large vessel occlusion (ELVO). The study, presented at the SNIS 23rd Annual Meeting, showed high rates of successful reperfusion and low complication rates. THUNDERBOLT, which recently received U.S. FDA clearance and CE Mark, is designed to improve clot removal in stroke treatment.
Magnendo Secures $18M Series A Financing to Transform Endovascular Access for Stroke Intervention
Magnendo Corp., an MIT spinout, announced the closing of an $18 million Series A financing round led by Penumbra, Inc. This funding will support the productization of Magnendo's magnetic robotic navigation platform and prepare for first-in-human clinical studies. The technology aims to improve the speed and reliability of neuro-endovascular procedures for acute ischemic stroke by making it easier for physicians to navigate complex vascular anatomy.
Penumbra stock reflects growth ambitions amid recent revenue gains
Penumbra Inc. (NYSE: PEN) exhibits growth ambitions, driven by expanding its stroke and vascular device portfolio and pursuing international markets. The company's recent financial reports show double-digit revenue growth in its neuro and vascular product lines, necessitating continued investment in R&D and commercial infrastructure. Investors are closely monitoring the balance between top-line expansion and profitability, especially given the competitive landscape and ongoing investment in innovation.
SA JPMorgan Mid-Cap Growth Portfolio's Penumbra Inc(PEN) Holding History
This article details the SA JPMorgan Mid-Cap Growth Portfolio's historical investment in Penumbra Inc (PEN). As of April 30, 2026, the portfolio held no shares of PEN, having made two purchases and three sales since 2025Q2. Based on transaction data and the current stock price, the portfolio realized an estimated gain of $1.22 million, or 22.06%, from its Penumbra holdings.
Penumbra reports THUNDER study results for THUNDERBOLT stroke device
Penumbra has released positive results from its THUNDER IDE study for the THUNDERBOLT computer-assisted vacuum thrombectomy system for ELVO stroke. The study achieved its performance goal with 87.5% successful reperfusion, a 64.8% first-pass success rate, and a median revascularization time of 20 minutes, with a low incidence of serious adverse events. The THUNDERBOLT device already has US FDA clearance and a CE mark.
Penumbra’s Thunderbolt stroke device meets study goals By Investing.com
Penumbra Inc. announced that its THUNDER study, evaluating the Thunderbolt computer assisted vacuum thrombectomy system for stroke patients, met its predefined performance goals, achieving successful reperfusion in 87.5% of cases. The device demonstrated a high rate of complete clot ingestion and a low rate of complications. Thunderbolt recently received U.S. FDA clearance and CE Mark, offering a new treatment option for acute ischemic stroke caused by large vessel occlusion.
